Identification

Name
Mirtazapine
Accession Number
DB00370  (APRD00685)
Type
Small Molecule
Groups
Approved
Description

Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. [Wikipedia]

Structure
Thumb
Synonyms
  • 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine
  • 6-Azamianserin
  • Mepirzapine
  • Mirtazapin
  • Mirtazapina
  • Mirtazapine
  • Mirtazapinum
External IDs
Org 3770
Product Ingredients
IngredientUNIICASInChI Key
Mirtazapine hydrochloride42CIX4573G207516-99-2SISMRXGXKXMBKT-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-mirtazapineTablet30 mgOralAuro Pharma Inc2013-10-16Not applicableCanada
Auro-mirtazapineTablet45 mgOralAuro Pharma Inc2013-10-16Not applicableCanada
Auro-mirtazapineTablet15 mgOralAuro Pharma Inc2013-10-16Not applicableCanada
Auro-mirtazapine ODTablet, orally disintegrating15 mgOralAuro Pharma Inc2010-12-20Not applicableCanada
Auro-mirtazapine ODTablet, orally disintegrating30 mgOralAuro Pharma Inc2010-12-20Not applicableCanada
Auro-mirtazapine ODTablet, orally disintegrating45 mgOralAuro Pharma Inc2010-12-20Not applicableCanada
Ava-mirtazapineTablet15 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-mirtazapineTablet30 mgOralAvanstra Inc2011-08-182014-08-21Canada
Co MirtazapineTablet30 mgOralCobalt Laboratories2006-03-232013-07-19Canada
Dom-mirtazapineTablet30 mgOralDominion Pharmacal2004-05-27Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mirtazapineTablet15 mgOralApotex Corporation2006-10-04Not applicableCanada
Apo-mirtazapineTablet30 mgOralApotex Corporation2006-10-04Not applicableCanada
Apo-mirtazapineTablet45 mgOralApotex Corporation2006-10-04Not applicableCanada
MirtazapineTablet, film coated15 mg/1OralAidarex Pharmaceuticals LLC2009-08-17Not applicableUs
MirtazapineTablet, orally disintegrating45 mg/1OralCitron Pharma LLC2006-02-28Not applicableUs
MirtazapineTablet, film coated15 mg/1OralNu Care Pharmaceuticals,inc.2007-08-22Not applicableUs
MirtazapineTablet, film coated15 mg/1OralUnit Dose Services2003-06-19Not applicableUs
MirtazapineTablet, film coated15 mg/1OralA S Medication Solutions2007-08-222017-06-20Us
MirtazapineTablet30 mg/1OralRemedy Repack2010-11-102017-03-02Us
MirtazapineTablet, film coated15 mg/1OralTeva2003-01-29Not applicableUs
International/Other Brands
Avanza (Schering-Plough) / Axit (Alphapharm) / Mirtabene (ratiopharm) / Mirtaz (Pinewood) / Mirtazon (Schering-Plough) / Norset (MSD France) / Promyrtil (Schering-Plough) / Remergil (Merck Sharp & Dohme) / Remergon (Organon) / Remeron SolTab / Rexer (Schering-Plough) / Zispin (Organon)
Categories
UNII
A051Q2099Q
CAS number
85650-52-8
Weight
Average: 265.3529
Monoisotopic: 265.157897623
Chemical Formula
C17H19N3
InChI Key
RONZAEMNMFQXRA-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
IUPAC Name
5-methyl-2,5,19-triazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(15),8,10,12,16,18-hexaene
SMILES
CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1

Pharmacology

Indication

For the treatment of major depressive disorder.

Structured Indications
Pharmacodynamics

Mirtazapine, an antidepressant of the piperazinoazepine class, is a tetracyclic compound with an anxiolytic effect. Mirtazapine has fewer ADRs than tricyclic antidepressants and is better tolerated. Selective blockade of specific serotonin receptors by mirtazapine likey minimizes side effects typical of other antidepressants.

Mechanism of action

Mirtazapine acts as an antagonist at central pre-synaptic alpha(2)-receptors, inhibiting negative feedback to the presynaptic nerve and causing an increase in NE release. Blockade of heteroreceptors, alpha(2)-receptors contained in serotenergic neurons, enhances the release of 5-HT, increasing the interactions between 5-HT and 5-HT1 receptors and contributing to the anxiolytic effects of mirtazapine. Mirtazapine also acts as a weak antagonist at 5-HT1 receptors and as a potent antagonist at 5-HT2 (particularly subtypes 2A and 2C) and 5-HT3 receptors. Blockade of these receptors may explain the lower incidence of adverse effects such as anxiety, insomnia, and nausea. Mirtazapine also exhibits significant antagonism at H1-receptors, resulting in sedation. Mirtazapine has no effects on the reuptake of either NE or 5-HT and has only minimal activity at dopaminergic and muscarinic receptors.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 3A
antagonist
Human
AAlpha-2A adrenergic receptor
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
UKappa-type opioid receptor
agonist
Human
NHistamine H1 receptor
antagonist
Human
UAlpha-2C adrenergic receptor
binder
Human
U5-hydroxytryptamine receptor 7
binding
Human
UAlpha-1 adrenergic receptors
binder
Human
UD(2) dopamine receptor
binder
Human
UD(3) dopamine receptorNot AvailableHuman
USodium-dependent noradrenaline transporter
binder
Human
USodium-dependent serotonin transporter
binder
Human
USodium-dependent dopamine transporter
binder
Human
U5-hydroxytryptamine receptor 2B
binder
Human
UD(1) dopamine receptor
binder
Human
UHistamine H3 receptor
antagonist
Human
UAlpha-1A adrenergic receptor
binder
Human
UBeta-1 adrenergic receptor
binder
Human
UBeta-2 adrenergic receptor
binder
Human
Absorption

Rapid and complete, but, due to first-pass metabolism, absolute bioavailability is 50%.

Volume of distribution
Not Available
Protein binding

85%

Metabolism

Mirtazapine is extensively metabolized by demethylation and hydroxylation followed by glucuronide conjugation. Cytochrome P450 2D6 and cytochrome P450 1A2 are involved in formation of the 8-hydroxy metabolite of mirtazapine, and cytochrome P450 3A4 is responsible for the formation of the N-desmethyl and N-oxide metabolites. Several metabolites possess pharmacological activity, but plasma levels are very low.

Route of elimination

This drug is known to be substantially excreted by the kidney (75%).

Half life

20-40 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include disorientation, drowsiness, impaired memory, and tachycardia. LD50 is 600-720mg/kg (oral, mice) and 320-490mg/kg (oral, rat) [PMID: 10333982]

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Mirtazapine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Mirtazapine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mirtazapine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Mirtazapine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mirtazapine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Mirtazapine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mirtazapine.Experimental, Illicit
4-MethoxyamphetamineMirtazapine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central neurotoxic activities of Mirtazapine.Experimental
AbirateroneThe serum concentration of Mirtazapine can be increased when it is combined with Abiraterone.Approved
AcenocoumarolMirtazapine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Acetophenazine.Approved
AdipiplonAdipiplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
AgmatineMirtazapine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Alaproclate.Experimental
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
AllopregnanoloneAllopregnanolone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Mirtazapine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Mirtazapine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Investigational
AltretamineAltretamine may increase the orthostatic hypotensive activities of Mirtazapine.Approved
AmiodaroneThe metabolism of Mirtazapine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Mirtazapine.Approved, Illicit
AmprenavirThe serum concentration of Mirtazapine can be increased when it is combined with Amprenavir.Approved
AnagrelideMirtazapine may increase the QTc-prolonging activities of Anagrelide.Approved
Antithrombin III humanThe serum concentration of Mirtazapine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Mirtazapine can be increased when it is combined with Apixaban.Approved
ApomorphineMirtazapine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineMirtazapine may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Mirtazapine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Mirtazapine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Mirtazapine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
Arsenic trioxideMirtazapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMirtazapine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
AsunaprevirThe serum concentration of Mirtazapine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Mirtazapine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Mirtazapine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Atorvastatin.Approved
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
AzelastineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
AzithromycinMirtazapine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Mirtazapine can be increased when combined with Barbexaclone.Experimental
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Illicit
BatimastatThe serum concentration of Mirtazapine can be increased when it is combined with Batimastat.Experimental
BedaquilineMirtazapine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Mirtazapine can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the central neurotoxic activities of Mirtazapine.Withdrawn
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
BenzamidineThe serum concentration of Mirtazapine can be increased when it is combined with Benzamidine.Experimental
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
BenzphetamineMirtazapine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Benzylpenicilloyl PolylysineMirtazapine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Mirtazapine.Approved
BetaxololThe metabolism of Mirtazapine can be decreased when combined with Betaxolol.Approved
BethanidineMirtazapine may decrease the antihypertensive activities of Bethanidine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Bifeprunox.Investigational
BivalirudinThe serum concentration of Mirtazapine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Mirtazapine can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Mirtazapine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Mirtazapine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
BrimonidineMirtazapine may decrease the antihypertensive activities of Brimonidine.Approved
BrofaromineBrofaromine may increase the central neurotoxic activities of Mirtazapine.Experimental
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
BromisovalBromisoval may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
BromocriptineMirtazapine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolBromperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Withdrawn
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
BuprenorphineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Mirtazapine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butaperazine.Experimental
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mirtazapine.Approved
CaffeineThe metabolism of Mirtazapine can be decreased when combined with Caffeine.Approved
CamostatThe serum concentration of Mirtazapine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Mirtazapine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Mirtazapine can be increased when it is combined with Candoxatrilat.Experimental
CanertinibCanertinib may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
CapecitabineThe metabolism of Mirtazapine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Mirtazapine can be increased when it is combined with Captopril.Approved
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cariprazine.Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
CaroxazoneCaroxazone may increase the central neurotoxic activities of Mirtazapine.Withdrawn
CelecoxibThe metabolism of Mirtazapine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Mirtazapine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Mirtazapine.Withdrawn
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ChloroquineMirtazapine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Mirtazapine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlorproethazine.Experimental
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational, Withdrawn
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
CholecalciferolThe metabolism of Mirtazapine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Mirtazapine can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Mirtazapine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Mirtazapine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Mirtazapine can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Mirtazapine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Mirtazapine can be increased when it is combined with Cinacalcet.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
CiprofloxacinMirtazapine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineMirtazapine may increase the vasopressor activities of Cirazoline.Experimental
CisaprideMirtazapine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Mirtazapine can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
ClonidineMirtazapine may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolClopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
ClorindioneMirtazapine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineClothiapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
ClotrimazoleThe metabolism of Mirtazapine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
CobicistatThe serum concentration of Mirtazapine can be increased when it is combined with Cobicistat.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
ConivaptanThe serum concentration of Mirtazapine can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Mirtazapine can be decreased when combined with Crisaborole.Approved
CrizotinibMirtazapine may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cyamemazine.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
CyclosporineThe metabolism of Mirtazapine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Cyproterone acetateThe serum concentration of Mirtazapine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Mirtazapine can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Mirtazapine can be decreased when it is combined with Dabrafenib.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Mirtazapine.Investigational
DarexabanThe serum concentration of Mirtazapine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Mirtazapine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Mirtazapine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Mirtazapine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Mirtazapine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Mirtazapine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Mirtazapine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Mirtazapine can be decreased when combined with Delavirdine.Approved
DeramciclaneDeramciclane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
DexmedetomidineMirtazapine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Mirtazapine.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Mirtazapine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dextromethorphan.Approved
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Vet Approved
DicoumarolMirtazapine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherDiethyl ether may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Mirtazapine.Approved, Illicit
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Mirtazapine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Mirtazapine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Mirtazapine.Experimental
DihydroergotamineMirtazapine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental, Illicit
DiltiazemThe metabolism of Mirtazapine can be decreased when combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
DiphenadioneMirtazapine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
DipivefrinMirtazapine may decrease the antihypertensive activities of Dipivefrin.Approved
DisopyramideMirtazapine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineDixyrazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dobutamine.Approved
DofetilideMirtazapine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronMirtazapine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneMirtazapine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
DosulepinThe metabolism of Mirtazapine can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
DoxycyclineThe metabolism of Mirtazapine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
DronedaroneMirtazapine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental, Illicit
DroxidopaMirtazapine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Mirtazapine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
EcabetThe serum concentration of Mirtazapine can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental, Illicit
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
EdoxabanThe serum concentration of Mirtazapine can be increased when it is combined with Edoxaban.Approved
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
ElafinThe serum concentration of Mirtazapine can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Mirtazapine.Approved, Investigational
EliglustatMirtazapine may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneEltanolone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
EnalaprilThe serum concentration of Mirtazapine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Mirtazapine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Mirtazapine can be increased when it is combined with Enalkiren.Experimental
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
EnzalutamideThe serum concentration of Mirtazapine can be decreased when it is combined with Enzalutamide.Approved
EphedraMirtazapine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Mirtazapine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinephrineMirtazapine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergonovine.Approved
ErgotamineMirtazapine may decrease the antihypertensive activities of Ergotamine.Approved
ErythromycinMirtazapine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Escitalopram.Approved, Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Ethyl biscoumacetateMirtazapine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Withdrawn
Ethyl chlorideEthyl chloride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
EtomidateMirtazapine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Etoperidone.Withdrawn
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Illicit, Vet Approved
EtravirineThe metabolism of Mirtazapine can be decreased when combined with Etravirine.Approved
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
FaldaprevirThe serum concentration of Mirtazapine can be increased when it is combined with Faldaprevir.Investigational
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
FelodipineThe metabolism of Mirtazapine can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fenoterol.Approved, Investigational
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirtazapine.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
FlecainideMirtazapine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
FloxuridineThe metabolism of Mirtazapine can be decreased when combined with Floxuridine.Approved
FluanisoneFluanisone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
FluconazoleThe metabolism of Mirtazapine can be decreased when combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
FluindioneMirtazapine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
FluorouracilThe metabolism of Mirtazapine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Mirtazapine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
Fluticasone propionateFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
FluvastatinThe metabolism of Mirtazapine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Mirtazapine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Mirtazapine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Mirtazapine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Mirtazapine can be increased when it is combined with Fosinopril.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the central neurotoxic activities of Mirtazapine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Mirtazapine can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
GabexateThe serum concentration of Mirtazapine can be increased when it is combined with Gabexate.Investigational
Gadobenic acidMirtazapine may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Investigational
GeldanamycinThe serum concentration of Mirtazapine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Mirtazapine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinMirtazapine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineGepefrine may decrease the sedative activities of Mirtazapine.Experimental
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
GM6001The serum concentration of Mirtazapine can be increased when it is combined with GM6001.Experimental
GoserelinMirtazapine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronMirtazapine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzMirtazapine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineMirtazapine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
HarmalineHarmaline may increase the central neurotoxic activities of Mirtazapine.Experimental
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mirtazapine.Approved, Investigational
HydracarbazineHydracarbazine may increase the central neurotoxic activities of Mirtazapine.Experimental
HydrocodoneMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Mirtazapine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
IbutilideMirtazapine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Mirtazapine can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Mirtazapine can be increased when it is combined with Idraparinux.Investigational
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ImatinibThe metabolism of Mirtazapine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Mirtazapine can be increased when it is combined with Imidapril.Investigational
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Mirtazapine can be decreased when combined with Indinavir.Approved
IndiplonIndiplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Mirtazapine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Mirtazapine.Approved
IproclozideIproclozide may increase the central neurotoxic activities of Mirtazapine.Withdrawn
IproniazidIproniazid may increase the central neurotoxic activities of Mirtazapine.Withdrawn
IrbesartanThe metabolism of Mirtazapine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Mirtazapine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the central neurotoxic activities of Mirtazapine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Isoetarine.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
IsoflurophateThe serum concentration of Mirtazapine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Mirtazapine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Isoprenaline.Approved
IsradipineThe metabolism of Mirtazapine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Mirtazapine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Mirtazapine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Mirtazapine can be increased when it is combined with Ixazomib.Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
KetoconazoleThe metabolism of Mirtazapine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Mirtazapine.Approved, Nutraceutical, Withdrawn
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
LapatinibThe metabolism of Mirtazapine can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Mirtazapine can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibMirtazapine may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe serum concentration of Mirtazapine can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Mirtazapine can be increased when it is combined with Letaxaban.Investigational
LeuprolideMirtazapine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
LevofloxacinMirtazapine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levosalbutamol.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Mirtazapine.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
LinagliptinThe serum concentration of Mirtazapine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Mirtazapine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Mirtazapine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Mirtazapine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Mirtazapine.Approved, Investigational
LisinoprilThe serum concentration of Mirtazapine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Mirtazapine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Mirtazapine.Approved
LobeglitazoneThe metabolism of Mirtazapine can be decreased when combined with Lobeglitazone.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Illicit
LofexidineMirtazapine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Mirtazapine can be decreased when combined with Lopinavir.Approved
LoprazolamLoprazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lorcaserin.Approved
LormetazepamLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
LosartanThe metabolism of Mirtazapine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Mirtazapine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
LuliconazoleThe serum concentration of Mirtazapine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Mirtazapine can be increased when it is combined with Lumacaftor.Approved
LumefantrineMirtazapine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Mirtazapine.Illicit, Investigational, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
ManidipineThe metabolism of Mirtazapine can be decreased when combined with Manidipine.Approved
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MebanazineMebanazine may increase the central neurotoxic activities of Mirtazapine.Withdrawn
MebicarMebicar may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MedazepamMedazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
MelagatranThe serum concentration of Mirtazapine can be increased when it is combined with Melagatran.Experimental
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MephedroneMephedrone may decrease the sedative activities of Mirtazapine.Investigational
MephentermineMirtazapine may increase the vasopressor activities of Mephentermine.Approved
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
MeptazinolMeptazinol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
MetaraminolMirtazapine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Mirtazapine.Experimental
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
MethamphetamineMirtazapine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MethotrimeprazineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineMirtazapine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Mirtazapine.Experimental
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MethylecgonineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
Methylene blueMirtazapine may increase the serotonergic activities of Methylene blue.Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Mirtazapine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Mirtazapine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Mirtazapine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mirtazapine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Mirtazapine.Approved, Investigational
MetyrosineMirtazapine may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Mirtazapine.Experimental
MexiletineThe metabolism of Mirtazapine can be decreased when combined with Mexiletine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
MidodrineMirtazapine may increase the vasopressor activities of Midodrine.Approved
Midomafetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Mirtazapine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Mirtazapine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Mirtazapine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the central neurotoxic activities of Mirtazapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
MirabegronThe metabolism of Mirtazapine can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Mirtazapine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may decrease the sedative activities of Mirtazapine.Experimental, Illicit
MoclobemideMoclobemide may increase the central neurotoxic activities of Mirtazapine.Approved
MoexiprilThe serum concentration of Mirtazapine can be increased when it is combined with Moexipril.Approved
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Moperone.Experimental
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Mosapramine.Experimental
MoxifloxacinMirtazapine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMirtazapine may decrease the antihypertensive activities of Moxonidine.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Mirtazapine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
NafamostatThe serum concentration of Mirtazapine can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
NaphazolineMirtazapine may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Naratriptan.Approved, Investigational
NefazodoneThe metabolism of Mirtazapine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Mirtazapine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Mirtazapine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Mirtazapine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the central neurotoxic activities of Mirtazapine.Withdrawn
NicardipineThe metabolism of Mirtazapine can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Mirtazapine.Approved, Investigational
NicorandilMirtazapine may increase the hypotensive activities of Nicorandil.Approved
NilotinibMirtazapine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
NitroaspirinThe serum concentration of Mirtazapine can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
NorepinephrineMirtazapine may decrease the antihypertensive activities of Norepinephrine.Approved
NorfluraneNorflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
OctamoxinOctamoxin may increase the central neurotoxic activities of Mirtazapine.Withdrawn
OfloxacinMirtazapine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
OlaparibThe metabolism of Mirtazapine can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Olodaterol.Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
OmapatrilatThe serum concentration of Mirtazapine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Mirtazapine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Orciprenaline.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
OsimertinibThe serum concentration of Mirtazapine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Mirtazapine can be increased when it is combined with Otamixaban.Investigational
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
OxethazaineOxethazaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Investigational
OxymetazolineMirtazapine may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxypertine.Experimental
PalbociclibThe serum concentration of Mirtazapine can be increased when it is combined with Palbociclib.Approved
PaliperidoneMirtazapine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Mirtazapine.Approved, Investigational
PanobinostatThe serum concentration of Mirtazapine can be increased when it is combined with Panobinostat.Approved, Investigational
PargylinePargyline may increase the central neurotoxic activities of Mirtazapine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Mirtazapine.Approved, Investigational
PazopanibMirtazapine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Mirtazapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolPenfluridol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
PentamidineMirtazapine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
PerflutrenMirtazapine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideMirtazapine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Mirtazapine can be increased when it is combined with Perindopril.Approved
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PhenazocinePhenazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
PhenelzinePhenelzine may increase the central neurotoxic activities of Mirtazapine.Approved
PhenibutPhenibut may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
PhenindioneMirtazapine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the central neurotoxic activities of Mirtazapine.Withdrawn
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PhenoperidinePhenoperidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PhenoxypropazinePhenoxypropazine may increase the central neurotoxic activities of Mirtazapine.Withdrawn
PhenprocoumonMirtazapine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenterminePhentermine may decrease the sedative activities of Mirtazapine.Approved, Illicit
PhenylephrineMirtazapine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineMirtazapine may decrease the antihypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
PhosphoramidonThe serum concentration of Mirtazapine can be increased when it is combined with Phosphoramidon.Experimental
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PioglitazoneThe metabolism of Mirtazapine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pirbuterol.Approved
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
PirlindolePirlindole may increase the central neurotoxic activities of Mirtazapine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Mirtazapine.Approved
PivhydrazinePivhydrazine may increase the central neurotoxic activities of Mirtazapine.Withdrawn
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PosaconazoleThe metabolism of Mirtazapine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleMirtazapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Mirtazapine.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PrimaquineMirtazapine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
PrinomastatThe serum concentration of Mirtazapine can be increased when it is combined with Prinomastat.Investigational
ProcainamideMirtazapine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
PropafenoneMirtazapine may increase the QTc-prolonging activities of Propafenone.Approved
PropanididPropanidid may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Propericiazine.Approved
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ProxibarbalProxibarbal may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
PseudoephedrineMirtazapine may decrease the antihypertensive activities of Pseudoephedrine.Approved
PyrimethamineThe metabolism of Mirtazapine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
QuinaprilThe serum concentration of Mirtazapine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineMirtazapine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineMirtazapine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineQuinisocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
RabeprazoleThe metabolism of Mirtazapine can be decreased when combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Mirtazapine can be increased when it is combined with Racecadotril.Investigational
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
RamiprilThe serum concentration of Mirtazapine can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Mirtazapine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the central neurotoxic activities of Mirtazapine.Approved
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
RemikirenThe serum concentration of Mirtazapine can be increased when it is combined with Remikiren.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Withdrawn
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
RifabutinThe metabolism of Mirtazapine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Mirtazapine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Mirtazapine can be increased when combined with Rifapentine.Approved
RisperidoneMirtazapine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
RitobegronRitobegron may decrease the sedative activities of Mirtazapine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Mirtazapine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Mirtazapine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Rizatriptan.Approved
RolapitantThe metabolism of Mirtazapine can be decreased when combined with Rolapitant.Approved
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
RopiniroleMirtazapine may decrease the antihypertensive activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
RosiglitazoneThe metabolism of Mirtazapine can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Mirtazapine.Approved
RotigotineMirtazapine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mirtazapine.Approved
S-3304The serum concentration of Mirtazapine can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the central neurotoxic activities of Mirtazapine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Salmeterol.Approved
SaquinavirThe metabolism of Mirtazapine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Mirtazapine can be increased when it is combined with Saxagliptin.Approved
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
SelegilineSelegiline may increase the central neurotoxic activities of Mirtazapine.Approved, Investigational, Vet Approved
SepranoloneSepranolone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Mirtazapine.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
SildenafilThe metabolism of Mirtazapine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Mirtazapine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Mirtazapine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Mirtazapine.Approved
SitagliptinThe serum concentration of Mirtazapine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Mirtazapine can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Sodium phosphateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sodium phosphate.Approved
SorafenibThe metabolism of Mirtazapine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolMirtazapine may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilThe serum concentration of Mirtazapine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Mirtazapine can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Mirtazapine can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
SulfadiazineThe metabolism of Mirtazapine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Mirtazapine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Mirtazapine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
SultoprideSultopride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sumatriptan.Approved, Investigational
SuvorexantMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Mirtazapine can be decreased when combined with Tamoxifen.Approved
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Mirtazapine.Approved
TelaprevirThe metabolism of Mirtazapine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinMirtazapine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Mirtazapine can be decreased when combined with Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
TemocaprilThe serum concentration of Mirtazapine can be increased when it is combined with Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Mirtazapine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Terbutaline.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Mirtazapine.Experimental
TeriflunomideThe serum concentration of Mirtazapine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Investigational
TheophyllineThe metabolism of Mirtazapine can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thioproperazine.Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Withdrawn
ThiorphanThe serum concentration of Mirtazapine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Mirtazapine.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
TicagrelorThe metabolism of Mirtazapine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Mirtazapine can be decreased when combined with Ticlopidine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
TilidineTilidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
TioclomarolMirtazapine may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Mirtazapine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineMirtazapine may decrease the antihypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Mirtazapine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Mirtazapine can be decreased when combined with Tolbutamide.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Withdrawn
ToloxatoneToloxatone may increase the central neurotoxic activities of Mirtazapine.Approved
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
TopiroxostatThe metabolism of Mirtazapine can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifeneMirtazapine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolMirtazapine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Mirtazapine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Tricaine methanesulfonateTricaine methanesulfonate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
TrichloroethyleneTrichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
TrifluperidolTrifluperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Vet Approved
TrimethoprimThe metabolism of Mirtazapine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
TropisetronTropisetron may increase the serotonergic activities of Mirtazapine.Approved, Investigational
UbenimexThe serum concentration of Mirtazapine can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Mirtazapine.Experimental
UlinastatinThe serum concentration of Mirtazapine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
ValsartanThe metabolism of Mirtazapine can be decreased when combined with Valsartan.Approved, Investigational
VandetanibMirtazapine may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Mirtazapine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Mirtazapine.Approved
VeraliprideVeralipride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
VerapamilThe metabolism of Mirtazapine can be decreased when combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Mirtazapine can be increased when it is combined with Vildagliptin.Approved, Investigational
Vinyl etherVinyl ether may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
VoriconazoleThe metabolism of Mirtazapine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
WarfarinMirtazapine may increase the anticoagulant activities of Warfarin.Approved
XenonXenon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Experimental
XimelagatranThe serum concentration of Mirtazapine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
XylometazolineMirtazapine may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Mirtazapine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Mirtazapine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Mirtazapine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ZofenoprilThe serum concentration of Mirtazapine can be increased when it is combined with Zofenopril.Experimental
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mirtazapine.Approved, Investigational
ZolpidemMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
ZucapsaicinThe metabolism of Mirtazapine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Leonid Metzger, "Methods for the preparation of mirtazapine intermediates." U.S. Patent US20020165238, issued November 07, 2002.

US20020165238
General References
  1. Gillman PK: A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25. [PubMed:16342227]
  2. Burrows GD, Kremer CM: Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. [PubMed:9090576]
  3. Velazquez C, Carlson A, Stokes KA, Leikin JB: Relative safety of mirtazapine overdose. Vet Hum Toxicol. 2001 Dec;43(6):342-4. [PubMed:11757992]
  4. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735]
  5. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. [PubMed:16272179]
  6. Fawcett J, Barkin RL: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998 Dec;51(3):267-85. [PubMed:10333982]
External Links
Human Metabolome Database
HMDB14514
KEGG Drug
D00563
KEGG Compound
C07570
PubChem Compound
4205
PubChem Substance
46506965
ChemSpider
4060
BindingDB
50115644
ChEBI
6950
ChEMBL
CHEMBL654
Therapeutic Targets Database
DAP000010
PharmGKB
PA450522
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Mirtazapine
ATC Codes
N06AX11 — Mirtazapine
AHFS Codes
  • 28:16.04.92 — Miscellaneous Antidepressants
FDA label
Download (904 KB)
MSDS
Download (57.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedSupportive CareMajor Depressive Disorder (MDD) / Neoplasms1
1CompletedNot AvailableHealthy Volunteers4
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionHealthy Volunteers1
1CompletedTreatmentObstructive Sleep Apnea (OSA)1
2Active Not RecruitingTreatmentAlcohol Use Disorder (AUD) / Major Depressive Disorder (MDD)1
2Active Not RecruitingTreatmentAmphetamine-Related Disorders1
2Active Not RecruitingTreatmentDepressive State / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
2CompletedPreventionAOD Craving / AODR Depressive State / Drug Abuse / Drug-induced Depressive State / Drug-withdrawal1
2CompletedTreatmentAlcohol Dependence2
2CompletedTreatmentDependence, Cocaine / Depressive State2
2CompletedTreatmentDepressive State / Excessive Daytime Sleepiness1
2CompletedTreatmentFibromyalgia Syndrome1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Substance Abuse1
2RecruitingTreatmentAlcohol Use Disorder (AUD) / Major Depressive Disorder (MDD)1
2TerminatedPreventionCancer, Advanced1
2WithdrawnSupportive CareAnorexic1
2, 3CompletedBasic ScienceDependence, Cocaine1
2, 3CompletedTreatmentDepressive State / Suicide, Attempted1
2, 3Not Yet RecruitingTreatmentCancer Associated Anorexia - Cachexia / Cancer, Advanced1
2, 3WithdrawnSupportive CareMalignant Neoplasm of Pancreas1
3CompletedTreatmentSleep1
3Not Yet RecruitingTreatmentAnorexic / Cachexia; Cancer1
3RecruitingPreventionCancer, Breast1
3RecruitingTreatmentAmphetamine Dependence / Heroin Dependence1
3RecruitingTreatmentAutism Spectrum Conditions/Disorders1
3RecruitingTreatmentDementias1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentAlzheimer's Disease (AD) / Sleep disorders and disturbances1
4CompletedNot AvailableMajor Depressive Disorder (MDD)1
4CompletedDiagnosticAffective Disorders / Depressive Disorders / Moods Disorders / Psychiatric Disorder NOS1
4CompletedOtherHealthy Controls / Major Depressive Disorder (MDD)1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentDepressive State1
4CompletedTreatmentDepressive State / Pain1
4CompletedTreatmentFeeling Anxious / PTSD1
4CompletedTreatmentMajor Depressive Disorder (MDD)3
4CompletedTreatmentNegative Symptoms / Schizophrenic Disorders1
4CompletedTreatmentPTSD1
4CompletedTreatmentPosttraumatic Stress Disorders1
4CompletedTreatmentUnipolar Major Depressive Episode1
4Not Yet RecruitingTreatmentDiagnosis and Treatment of Depression1
4RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
4RecruitingDiagnosticAsthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)1
4RecruitingTreatmentDepressive Disorders1
4TerminatedTreatmentDepressive State1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentFunctional Dyspepsia1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)2
Not AvailableActive Not RecruitingTreatmentAnorexic / Cancer, Advanced / Obese experiencing rapid weight loss / Sleeplessness1
Not AvailableActive Not RecruitingTreatmentDepressive State2
Not AvailableCompletedNot AvailableAlzheimer's Disease (AD) / Dementia, Mixed / Dementias / Obese experiencing rapid weight loss1
Not AvailableCompletedPreventionDepressive State / Feeling Anxious1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableRecruitingTreatmentAdverse Reaction to Drug / Depressive State1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Chronic Diseases / Depressive State / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableRecruitingTreatmentAntidepressant Drug Adverse Reaction / Depressive State1
Not AvailableRecruitingTreatmentDepressive State1
Not AvailableRecruitingTreatmentDepressive State / Depressive Symptoms1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1
Not AvailableWithdrawnTreatmentAmphetamine Dependence1

Pharmacoeconomics

Manufacturers
  • Actavis totowa llc
  • Aurobindo pharma ltd inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Organon usa inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
TabletOral15 mg/1
TabletOral30 mg/1
TabletOral45 mg/1
TabletOral7.5 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral45 mg/1
Tablet, film coatedOral7.5 mg/1
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral30 mg/1
Tablet, orally disintegratingOral45 mg/1
TabletOral45 mg
TabletOral30 mg
Tablet, orally disintegratingOral15 mg
Tablet, orally disintegratingOral30 mg
Tablet, orally disintegratingOral45 mg
TabletOral15 mg
Prices
Unit descriptionCostUnit
Remeron SolTab 30 45 mg Dispersible Tablet Box114.4USD box
Remeron SolTab 30 15 mg Dispersible Tablet Box107.58USD box
Remeron SolTab 30 30 mg Dispersible Tablet Box107.27USD box
Mirtazapine 30 45 mg Dispersible Tablet Box88.95USD box
Mirtazapine 30 30 mg Dispersible Tablet Box83.48USD box
Mirtazapine 30 15 mg Dispersible Tablet Box81.02USD box
Remeron 45 mg tablet4.61USD tablet
Remeron 15 mg tablet4.42USD tablet
Remeron 45 mg soltab3.57USD tablet
Remeron 30 mg soltab3.55USD tablet
Remeron 30 mg tablet3.47USD tablet
Remeron 15 mg soltab3.26USD tablet
Mirtazapine 45 mg tablet2.91USD tablet
Mirtazapine 30 mg tablet2.85USD tablet
Mirtazapine 15 mg tablet2.77USD tablet
Mirtazapine 7.5 mg tablet2.56USD tablet
Apo-Mirtazapine 30 mg Tablet0.73USD tablet
Mylan-Mirtazapine 30 mg Tablet0.73USD tablet
Novo-Mirtazapine 30 mg Tablet0.73USD tablet
Phl-Mirtazapine 30 mg Tablet0.73USD tablet
Pms-Mirtazapine 30 mg Tablet0.73USD tablet
Ratio-Mirtazapine 30 mg Tablet0.73USD tablet
Sandoz Mirtazapine 30 mg Tablet0.73USD tablet
Pms-Mirtazapine 15 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878No1993-01-122010-01-12Us
CA2386547No2010-06-082020-10-09Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)114-116 °CNot Available
water solubilitySlightNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.1 mg/mLALOGPS
logP2.9ALOGPS
logP3.21ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)6.67ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity82.66 m3·mol-1ChemAxon
Polarizability30.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9873
Blood Brain Barrier+0.9855
Caco-2 permeable+0.7283
P-glycoprotein substrateSubstrate0.8462
P-glycoprotein inhibitor IInhibitor0.6148
P-glycoprotein inhibitor IINon-inhibitor0.8975
Renal organic cation transporterInhibitor0.7956
CYP450 2C9 substrateNon-substrate0.7988
CYP450 2D6 substrateSubstrate0.7894
CYP450 3A4 substrateNon-substrate0.5148
CYP450 1A2 substrateInhibitor0.8503
CYP450 2C9 inhibitorNon-inhibitor0.6675
CYP450 2D6 inhibitorInhibitor0.7222
CYP450 2C19 inhibitorNon-inhibitor0.6206
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6031
Ames testNon AMES toxic0.8079
CarcinogenicityNon-carcinogens0.9742
BiodegradationNot ready biodegradable0.9919
Rat acute toxicity2.5197 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7532
hERG inhibition (predictor II)Inhibitor0.7455
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-57eb768d0827fa54b248
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014j-0490000000-4baae8cca5ab43f65dd9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0910000000-c22ff3266fd0a936312d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-ba0af76733c8ba5925ce
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-1b44d823d26f0e0bcd4d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0090000000-3582965e74f282e6bdea
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-3290000000-d8839a66bb5976dbb5fd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006t-5930000000-9d1fc48d559a70f6a0e1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-2910000000-7c8bdce5145b9fd2fda0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-1900000000-05e225af5ed24498466e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0005-1900000000-f4e13abbfa0358ad282c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kf-2900000000-0a101b135d8e91d9b9a2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-2900000000-6c01bee517524e647dc2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014u-3900000000-7b5b5e6493206d8c9a67
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014j-0890000000-37665999329d651a1038
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0920000000-0a76314cf99840d246ad
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-1920000000-27fff664f04384263f02
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014j-0790000000-5653705decf2e797e122
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-2910000000-63ecec66eeef916c6ccf

Taxonomy

Description
This compound belongs to the class of organic compounds known as piperazinoazepines. These are compounds containing a piperazinoazepine skeleton, which consists of an azepine ring fused to a piperazine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperazinoazepines
Sub Class
Not Available
Direct Parent
Piperazinoazepines
Alternative Parents
Benzazepines / Dialkylarylamines / N-methylpiperazines / Azepines / Aralkylamines / Pyridines and derivatives / Imidolactams / Benzenoids / Heteroaromatic compounds / Trialkylamines
show 3 more
Substituents
Benzazepine / Piperazino-azepine / Dialkylarylamine / Azepine / N-methylpiperazine / N-alkylpiperazine / Aralkylamine / Imidolactam / Benzenoid / Pyridine
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzazepine, tetracyclic antidepressant (CHEBI:6950)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. [PubMed:10446734]
  2. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735]
  3. Nutt DJ: Care of depressed patients with anxiety symptoms. J Clin Psychiatry. 1999;60 Suppl 17:23-7; discussion 46-8. [PubMed:10446738]
  4. Laakmann G, Schule C, Baghai T, Waldvogel E: Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology. 1999 Oct;24(7):769-84. [PubMed:10451911]
  5. Waldinger MD, Berendsen HH, Schweitzer DH: Treatment of hot flushes with mirtazapine: four case reports. Maturitas. 2000 Oct 31;36(3):165-8. [PubMed:11063897]
  6. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. [PubMed:10446734]
  2. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735]
  3. Kast RE, Foley KF: Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl). 2007 Jul;16(4):351-4. [PubMed:17587360]
  4. de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. [PubMed:8930006]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Garcia-Sevilla JA, Ventayol P, Perez V, Rubovszky G, Puigdemont D, Ferrer-Alcon M, Andreoli A, Guimon J, Alvarez E: Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology. 2004 Mar;29(3):580-8. [PubMed:14628003]
  2. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047]
  3. Besson A, Haddjeri N, Blier P, de Montigny C: Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol. 2000 May;10(3):177-88. [PubMed:10793320]
  4. Schreiber S, Bleich A, Pick CG: Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression? J Mol Neurosci. 2002 Feb-Apr;18(1-2):143-9. [PubMed:11931344]
  5. Rogoz Z, Wrobel A, Dlaboga D, Maj J, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. J Physiol Pharmacol. 2002 Mar;53(1):105-16. [PubMed:11939713]
  6. Rogoz Z, Wrobel A, Dlaboga D, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. Pol J Pharmacol. 2002 Jul-Aug;54(4):381-9. [PubMed:12523492]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Benelli A, Frigeri C, Bertolini A, Genedani S: Influence of mirtazapine on the sexual behavior of male rats. Psychopharmacology (Berl). 2004 Jan;171(3):250-8. Epub 2003 Nov 13. [PubMed:14615872]
  2. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339]
  3. Meert TF, Melis W, Aerts N, Clincke G: Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats. Behav Pharmacol. 1997 Aug;8(4):353-63. [PubMed:9832994]
  4. Millan MJ: Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. [PubMed:16433010]
  5. Dekeyne A, Iob L, Millan MJ: Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats. Psychopharmacology (Berl). 2001 Jan;153(3):389-92. [PubMed:11271412]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Schreiber S, Rigai T, Katz Y, Pick CG: The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res Bull. 2002 Sep 30;58(6):601-5. [PubMed:12372565]
Details
6. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539]
  3. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binding
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539]
  3. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539]
  3. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. [PubMed:12109911]
  4. PDSP Ki Database [Link]
Details
10. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. [PubMed:12109911]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539]
Details
11. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. [PubMed:12109911]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. de Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57 Suppl 4:19-25. [PubMed:8636062]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539]
  4. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539]
  3. de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. [PubMed:8930006]
  4. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. Signals through the inhibition of adenylate cyclase and displays high constitutive a...
Gene Name
HRH3
Uniprot ID
Q9Y5N1
Uniprot Name
Histamine H3 receptor
Molecular Weight
48670.81 Da
References
  1. Pytliak M, Vargova V, Mechirova V, Felsoci M: Serotonin receptors - from molecular biology to clinical applications. Physiol Res. 2011;60(1):15-25. Epub 2010 Oct 15. [PubMed:20945968]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539]
  4. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49